{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T22:51:25Z","timestamp":1788648685968,"version":"build-2803163510"},"reference-count":54,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>This review summarises the major novel treatment options for children with juvenile idiopathic arthritis (JIA) since the pandemic, reflecting not only on advancements in therapeutics but also approach to management and research.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Several recent international paediatric trials have been important in advancing understanding of JIA and furthering available treatment options. Biologic and small molecule agents were demonstrated to be effective and safe in recalcitrant or severe JIA (including extra-articular complications), mirroring the adult equivalent diseases.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Although joint and overall health have vastly improved for young people with JIA, ongoing international collaboration, critical review of treatment strategies and high quality research are essential to optimize outcomes.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000001028","type":"journal-article","created":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T10:26:37Z","timestamp":1716373597000},"page":"328-335","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Novel therapies in juvenile idiopathic arthritis"],"prefix":"10.1097","volume":"36","author":[{"given":"Anne M.","family":"Sage","sequence":"first","affiliation":[{"name":"Department of Paediatric Rheumatology, Bristol Royal Hospital for Children, Bristol"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah L.N.","family":"Clarke","sequence":"additional","affiliation":[{"name":"Department of Paediatric Rheumatology, Bristol Royal Hospital for Children, Bristol"},{"name":"Department of Paediatrics, Royal United Hospital Bath, Bath"},{"name":"MRC Integrative Epidemiology Unit and School of Population Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athimalaipet V.","family":"Ramanan","sequence":"additional","affiliation":[{"name":"Department of Paediatric Rheumatology, Bristol Royal Hospital for Children, Bristol"},{"name":"School of Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,5,22]]},"reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12969-020-00443-8","article-title":"Global prevalence estimates of three chronic musculoskeletal conditions: club foot, juvenile idiopathic arthritis and juvenile systemic lupus erythematosus","volume":"18","author":"Dave","year":"2020","journal-title":"Pediatr Rheumatol Online J"},{"key":"R2-20250526","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision","volume":"31","author":"Petty","year":"2004","journal-title":"Edmonton J Rheumatol"},{"key":"R3-20250526","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3899\/jrheum.180168","article-title":"Toward new classification criteria for juvenile idiopathic arthritis: first steps, pediatric rheumatology international trials organization international consensus","volume":"46","author":"Martini","year":"2019","journal-title":"J Rheumatol"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41584-021-00590-6","article-title":"Biological classification of childhood arthritis: roadmap to a molecular nomenclature","volume":"17","author":"Nigrovic","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s11926-020-0880-3","article-title":"The challenges and opportunities of classifying childhood arthritis","volume":"22","author":"Rumsey","year":"2020","journal-title":"Curr Rheumatol Rep"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1136\/annrheumdis-2014-205372","article-title":"The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort","volume":"74","author":"Guzman","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12969-023-00885-w","article-title":"Predictors of persisting pain in children with juvenile idiopathic arthritis: a case control study nested in the ReACCh-Out cohort","volume":"21","author":"McGrath","year":"2023","journal-title":"Pediatr Rheumatol Online J"},{"key":"R8-20250526","doi-asserted-by":"crossref","first-page":"e002520","DOI":"10.1136\/rmdopen-2022-002520","article-title":"Medication burden in young adults with juvenile idiopathic arthritis: data from a multicentre observational study","volume":"8","author":"Montag","year":"2022","journal-title":"RMD Open"},{"key":"R9-20250526","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-019-1866-2","article-title":"Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study","volume":"21","author":"Wollenhaupt","year":"2019","journal-title":"Arthr Res Ther"},{"key":"R10-20250526","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s40744-020-00209-4","article-title":"Safety and efficacy of tofacitinib in patients with active psoriatic arthritis: interim analysis of OPAL balance, an open-label, long-term extension study","volume":"7","author":"Nash","year":"2020","journal-title":"Rheumatol Ther"},{"key":"R11-20250526","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12969-017-0212-y","article-title":"Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study","volume":"15","author":"Ruperto","year":"2017","journal-title":"Pediatr Rheumatol Online J"},{"key":"R12-20250526","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/S0140-6736(21)01255-1","article-title":"Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial","volume":"398","author":"Ruperto","year":"2021","journal-title":"Lancet"},{"key":"R13-20250526","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s40257-023-00764-w","article-title":"Efficacy and safety of baricitinib in patients with severe alopecia areata over 52 weeks of continuous therapy in two Phase III trials (BRAVE-AA1 and BRAVE-AA2)","volume":"24","author":"Kwon","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"R14-20250526","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","article-title":"Baricitinib in patients with refractory rheumatoid arthritis","volume":"374","author":"Genovese","year":"2016","journal-title":"N Engl J Med"},{"key":"R15-20250526","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(23)00921-2","article-title":"Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial","volume":"402","author":"Ramanan","year":"2023","journal-title":"Lancet"},{"key":"R16-20250526","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","article-title":"Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Burmester","year":"2018","journal-title":"Lancet"},{"key":"R17-20250526","first-page":"312","article-title":"Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"R18-20250526","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","article-title":"Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials","volume":"397","author":"Guttman-Yassky","year":"2021","journal-title":"Lancet"},{"key":"R19-20250526","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s40744-023-00557-x","article-title":"Long-term efficacy and safety of upadacitinib in patients with rheumatoid arthritis: final results from the BALANCE-EXTEND Open-Label Extension Study","volume":"10","author":"Kivitz","year":"2023","journal-title":"Rheumatol Ther"},{"issue":"(Suppl 1)","key":"R20-20250526","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1136\/annrheumdis-2023-eular.3987","article-title":"OP0164 Safety and efficacy of upadacitinib for pediatric patients with polyarticular course juvenile idiopathic arthritis: an interim analysis of an open-label, phase 1 trial","volume":"82","author":"Brunner","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R21-20250526","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N Engl J Med"},{"key":"R22-20250526","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13075-023-03051-5","article-title":"Two-year imaging outcomes from a phase 3 randomized trial of secukinumab in patients with nonradiographic axial spondyloarthritis","volume":"25","author":"Braun","year":"2023","journal-title":"Arthr Res Ther"},{"key":"R23-20250526","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human antiinterleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"key":"R24-20250526","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1136\/ard-2022-222849","article-title":"Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial","volume":"82","author":"Brunner","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R25-20250526","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/bjd.19147","article-title":"Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS)","volume":"183","author":"Paller","year":"2020","journal-title":"Br J Dermatol"},{"key":"R26-20250526","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1001\/jamadermatol.2022.0655","article-title":"Long-term efficacy and safety of up to 108 weeks of ixekizumab in pediatric patients with moderate to severe plaque psoriasis: the IXORA-PEDS Randomized Clinical Trial","volume":"158","author":"Paller","year":"2022","journal-title":"JAMA Dermatol"},{"key":"R27-20250526","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jaad.2015.07.002","article-title":"Ustekinumab in adolescent patients age 12 to 17\u200ayears with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study","volume":"73","author":"Landells","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"R28-20250526","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/bjd.19018","article-title":"Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients (\u2265 6 to < 12\u200ayears of age): efficacy, safety, pharmacokinetic and biomarker results from the open-label CADMUS Jr study","volume":"183","author":"Philipp","year":"2020","journal-title":"Br J Dermatol"},{"key":"R29-20250526","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s40272-022-00533-y","article-title":"Intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis and juvenile psoriatic arthritis and subcutaneous ustekinumab in patients with juvenile psoriatic arthritis: extrapolation of data from studies in adults and adjacent pediatric populations","volume":"24","author":"Leu","year":"2022","journal-title":"Paediatr Drugs"},{"key":"R30-20250526","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s41584-023-01042-z","article-title":"Treatment of systemic juvenile idiopathic arthritis","volume":"19","author":"Hinze","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"R31-20250526","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s12969-022-00768-6","article-title":"First-line options for systemic juvenile idiopathic arthritis treatment: an observational study of childhood arthritis and rheumatology research alliance consensus treatment plans","volume":"20","author":"Beukelman","year":"2022","journal-title":"Pediatr Rheumatol Online J"},{"key":"R32-20250526","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1002\/art.21774","article-title":"Predictors of disease course and remission in systemic juvenile idiopathic arthritis: significance of early clinical and laboratory features","volume":"54","author":"Singh-Grewal","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R33-20250526","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/art.38296","article-title":"Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study","volume":"66","author":"Vastert","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"R34-20250526","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1002\/art.40865","article-title":"Treatment to target using recombinant interleukin-1 receptor antagonist as first-line monotherapy in new-onset systemic juvenile idiopathic arthritis: results from a five-year follow-up study","volume":"71","author":"Ter Haar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R35-20250526","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1136\/annrheumdis-2019-216040","article-title":"Emergent high fatality lung disease in systemic juvenile arthritis","volume":"78","author":"Saper","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R36-20250526","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.3390\/diagnostics12123095","article-title":"Lung involvement in systemic juvenile idiopathic arthritis: a narrative review","volume":"12","author":"Petrongari","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"R37-20250526","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1002\/art.42137","article-title":"The conundrum of lung disease and drug hypersensitivity-like reactions in systemic juvenile idiopathic arthritis","volume":"74","author":"Binstadt","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"R38-20250526","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1002\/art.41073","article-title":"Systemic juvenile idiopathic arthritis-associated lung disease: characterization and risk factors","volume":"71","author":"Schulert","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R39-20250526","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.3390\/jcm12072702","article-title":"Rescue of pap-mas in systemic JIA using janus kinase inhibitors, case report and systematic review","volume":"12","author":"Zekre","year":"2023","journal-title":"J Clin Med"},{"key":"R40-20250526","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1002\/art.38802","article-title":"Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients","volume":"66","author":"Minoia","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"R41-20250526","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1136\/ard-2022-223739","article-title":"Efficacy and safety of emapalumab in macrophage activation syndrome","volume":"82","author":"Benedetti","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R42-20250526","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1093\/rheumatology\/keac440","article-title":"JAK inhibitors in difficult-to-treat adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis","volume":"62","author":"Gillard","year":"2022","journal-title":"Rheumatology"},{"key":"R43-20250526","first-page":"11","article-title":"JAK inhibitors in systemic juvenile idiopathic arthritis","author":"He","year":"2023","journal-title":"Front Pediatr"},{"key":"R44-20250526","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1745-6215-15-14","article-title":"A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial)","volume":"15","author":"Ramanan","year":"2014","journal-title":"Trials"},{"key":"R45-20250526","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1016\/S2665-9913(20)30008-4","article-title":"Tocilizumab in patients with anti-TNF refractory juvenile idiopathic arthritis-associated uveitis (APTITUDE): a multicentre, single-arm, phase 2 trial","volume":"2","author":"Ramanan","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"R46-20250526","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1186\/s13063-021-05651-5","article-title":"Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT)","volume":"22","author":"Ramanan","year":"2021","journal-title":"Trials"},{"key":"R47-20250526","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1136\/ard-2022-222553","article-title":"Towards molecular-pathology informed clinical trials in childhood arthritis to achieve precision medicine in juvenile idiopathic arthritis","volume":"82","author":"Wedderburn","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R48-20250526","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1136\/annrheumdis-2018-213030","article-title":"Treating juvenile idiopathic arthritis to target: recommendations of an international task force","volume":"77","author":"Ravelli","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R49-20250526","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-023-03166-9","article-title":"Influence of the timing of biological treatment initiation on juvenile idiopathic arthritis long-term outcomes","volume":"25","author":"Oliveira Ramos","year":"2023","journal-title":"Arthritis Res Ther"},{"key":"R50-20250526","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/acr.23709","article-title":"Time of disease-modifying antirheumatic drug start in juvenile idiopathic arthritis and the likelihood of a drug-free remission in young adulthood","volume":"71","author":"Minden","year":"2019","journal-title":"Arthritis Care Res"},{"key":"R51-20250526","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3899\/jrheum.190268","article-title":"Outcome monitoring and clinical decision support in polyarticular juvenile idiopathic arthritis","volume":"47","author":"Buckley","year":"2020","journal-title":"J Rheumatol"},{"key":"R52-20250526","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1136\/annrheumdis-2018-213902","article-title":"Treat to target (drug-free) inactive disease in DMARD-naive juvenile idiopathic arthritis: 24-month clinical outcomes of a three-armed randomised trial","volume":"78","author":"Hissink Muller","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R53-20250526","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1136\/annrheumdis-2019-216843","article-title":"Treat-to-target study for improved outcome in polyarticular juvenile idiopathic arthritis","volume":"79","author":"Klein","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R54-20250526","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S2352-4642(19)30027-6","article-title":"Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study","volume":"3","author":"Consolaro","year":"2019","journal-title":"Lancet Child Adolesc Health"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001028","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T21:16:50Z","timestamp":1748294210000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,22]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000001028","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,22]]}}}